Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer's prevention
LONDON — Eli Lilly, the world’s biggest drugmaker, appears to be getting more ambitious about tackling brain diseases. Last week, the company announced it would pay $2.8 billion upfront to acquire AtaiBeckley, which ...
Carole Ho, president of Lilly Neuroscience July 22, 2026 10:00 AM EDT PeopleR&DPharma Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer's prevention Ryan Cross Senior Science Correspondent LONDON — Eli Lilly, the world’s biggest drugmaker, appears to be getting more ambitious about tackling brain diseases. Last week, the company announced it would pay … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that